More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...

The FDA expedited drug review activity in December 2025 includes six fast-tracked therapies and the first National ...

Target action dates for drugs sponsored by Sanofi, Boehringer Ingelheim and Disc Medicine have also been pushed back despite ...

FDA delays drug reviews for two priority voucher drugs amid safety and efficacy concerns, extending timelines for Sanofi and Disc Medicine products.

Three key themes emerged across the mifepristone documents: consistent safety findings, lack of ideological bias in staff ...

The Senate’s health committee convened its first hearing of the year on the efficacy of the chemical abortion drug ...

Food and Drug Administration ​has extended its review for ‌the expanded use of Travere Therapeutics’ ‌drug to treat a type of ...